Fig. 7
CXCR4/WNT5A/β-catenin axis activation is associated with palbociclib resistance in patients with breast cancer. Patients with advanced breast cancer who progressed with palbociclib treatment were enrolled, and the paired naive and progressed tumor tissues were collected. Then immunohistochemistry was performed to analyze the protein expression of CXCR4, WNT5A and β-catenin. The stain scores were calculated and the expression difference of them between the before palbociclib treatment group and the palbociclib-resistant group was analyzed. Representative images showed in panel a, and quantification analysis showed in panel b. The p values were determined by paired Student’s test, **p < 0.01, *p < 0.05. Scale bars represent 50 μm